I'm LongbridgeAI, I can summarize articles.Nano-X Imaging (NNOX) holds a 'Moderate Buy' consensus from six analysts, with an average price target of $4.00. Recent analyst actions include D. Boral Capital's buy rating and Zacks Research's upgrade to hold. Institutional investors like UBS and JPMorgan increased holdings in Q2. The stock opened at $1.24, following quarterly earnings of -$0.16 EPS. Key news includes positive clinical data for Nanox.AI and negative sentiment regarding federal securities class action lawsuits.
Shares of Nano-X Imaging Ltd. (NASDAQ:NNOX - Get Free Report) have been given an average recommendation of "Moderate Buy" by the six ratings firms that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, one has assigned a buy rating and two have given a strong buy rating to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $4.00.
Get Nano-X Imaging alerts:
- Nano-X Imaging NASDAQ: NNOX Stock: Reimagining the X-Ray
Several brokerages have recently issued reports on NNOX. D. Boral Capital reissued a "buy" rating and set a $5.00 price target on shares of Nano-X Imaging in a report on Monday, April 20th. Weiss Ratings restated a "sell (e+)" rating on shares of Nano-X Imaging in a research note on Friday, April 10th. Alliance Global Partners reaffirmed a "neutral" rating and set a $3.00 price target (down from $5.00) on shares of Nano-X Imaging in a report on Tuesday. Finally, Zacks Research upgraded Nano-X Imaging from a "strong sell" rating to a "hold" rating in a research report on Monday, June 22nd.
Read Our Latest Analysis on Nano-X Imaging
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently modified their holdings of NNOX. AQR Capital Management LLC acquired a new position in shares of Nano-X Imaging during the first quarter valued at $178,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in Nano-X Imaging by 232.4% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,160,806 shares of the company's stock worth $10,793,000 after purchasing an additional 1,510,806 shares during the period. Geode Capital Management LLC lifted its holdings in Nano-X Imaging by 17.5% in the second quarter. Geode Capital Management LLC now owns 810,322 shares of the company's stock worth $4,189,000 after purchasing an additional 120,460 shares during the period. Cetera Investment Advisers grew its position in Nano-X Imaging by 82.0% in the 2nd quarter. Cetera Investment Advisers now owns 48,056 shares of the company's stock valued at $248,000 after buying an additional 21,657 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its position in Nano-X Imaging by 61.5% in the 2nd quarter. JPMorgan Chase & Co. now owns 65,783 shares of the company's stock valued at $340,000 after buying an additional 25,048 shares in the last quarter. Institutional investors own 21.49% of the company's stock.
Nano-X Imaging Price Performance
Shares of NNOX stock opened at $1.24 on Wednesday. The firm has a fifty day moving average of $1.68 and a two-hundred day moving average of $2.28. The firm has a market cap of $86.29 million, a P/E ratio of -0.78 and a beta of 1.24. Nano-X Imaging has a 1-year low of $0.73 and a 1-year high of $5.69.
Nano-X Imaging (NASDAQ:NNOX - Get Free Report) last announced its quarterly earnings results on Thursday, June 25th. The company reported ($0.16) earnings per share (EPS) for the quarter. The company had revenue of $4.31 million during the quarter. Nano-X Imaging had a negative return on equity of 70.96% and a negative net margin of 716.44%. On average, sell-side analysts expect that Nano-X Imaging will post -0.6 EPS for the current year.
Key Nano-X Imaging News
Here are the key news stories impacting Nano-X Imaging this week:
- Positive Sentiment: Nano-X said new clinical study data for its Nanox.AI cardiac solution will be presented at SCCT 2026, with Brigham and Women’s Hospital abstracts highlighting high agreement with expert assessment and potential use in preventive care. Article: New Clinical Study Data, Featuring Nanox.AI Cardiac Solution to Be Presented at SCCT 2026
- Neutral Sentiment: Alliance Global Partners reiterated a “Neutral” rating on Nano-X Imaging, but lowered its price target to $3 from $5, signaling reduced near-term confidence even though it still implies upside from current levels. Article: Nano-X Imaging's (NNOX) "Neutral" Rating Reiterated at Alliance Global Partners
- Negative Sentiment: Multiple law firms announced or reiterated a federal securities class action against Nano-X Imaging, with claims tied to purchases made between March 31, 2025 and April 17, 2026. Article: Pomerantz Law Firm Announces the Filing of a Class Action Against Nano-X Imaging Ltd. and Certain Officers – NNOX
- Negative Sentiment: Several firms, including Rosen, Kirby McInerney, Glancy Prongay Wolke & Rotter, and Faruqi & Faruqi, are urging investors to act before the August 11, 2026 lead-plaintiff deadline, keeping legal risk in focus. Article: REMINDER: Nano-X Imaging Ltd. Investors With Significant Losses Must Act By August 11, 2026
About Nano-X Imaging
(Get Free Report)Nano-X Imaging Ltd. is a medical technology company developing and commercializing a digital X-ray imaging platform designed to lower the cost and increase the accessibility of diagnostic imaging. Its flagship product, the Nanox.ARC, leverages a proprietary micro-electromechanical system (MEMS) based digital X-ray source and advanced image processing software to provide 2D and 3D imaging capabilities on a compact footprint. The system aims to streamline radiology workflows and facilitate point-of-care diagnostics in hospitals, clinics and outpatient settings.
The Nanox.ARC platform integrates a novel cold cathode X-ray source, which enables multiple emission points without the need for rotating anode tubes.
Featured Articles
- Five stocks we like better than Nano-X Imaging
- Apple and Broadcom Forge a Decade-Long Silicon Fortress
- SK Hynix’s Nasdaq Listing Could Reset the AI Memory Trade
- The AI Chip Sell-Off Looks Scary, But the Real Story May Be Liquidity
- Palantir's CEO Just Called Out OpenAI and Anthropic
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Nano-X Imaging Right Now?
Before you consider Nano-X Imaging, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nano-X Imaging wasn't on the list.
While Nano-X Imaging currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here